Body · topic 1 of 4
Heart health
ApoB · LDL-C · Lp(a) · hs-CRP — screening bands, not treatment targets
Video walkthrough — Heart Health
In production, coming soon
For ApoB and LDL-C in particular, clinical targets are set by a person's overall cardiovascular risk category — a value in the "borderline" band may be perfectly appropriate for one person and a treatment trigger for another. Verve classifies against population screening bands and always defers to a clinician.
ApoB — ESC/EAS 2019 Dyslipidaemia Guidelines
Risk-stratified ApoB goals: <65 mg/dL very-high risk, <80 mg/dL high risk, <100 mg/dL moderate risk. Verve screens against the <80 / <100 boundaries. ApoB counts atherogenic particles directly — one per LDL, IDL, VLDL and Lp(a) particle — capturing risk LDL-C alone can miss.
PMID 31504418 →
LDL-C — NCEP ATP III
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Optimal <100, near-optimal 100–129, borderline-high 130–159, high 160–189, very high ≥190 mg/dL. Verve collapses the upper bands into one “elevated” tier for screening.
PMID 11368702 →
Lp(a) — EAS 2022 Consensus Statement
Risk rises continuously; commonly cited bands are <75 nmol/L (~<30 mg/dL) low, 75–125 nmol/L (30–50 mg/dL) intermediate, >125 nmol/L (>50 mg/dL) high. Lp(a) is ~90% genetically determined and stable through life — a single measurement is usually sufficient.
PMID 36036785 →
hs-CRP — AHA/CDC Scientific Statement 2003
Relative cardiovascular risk bands: <1.0 mg/L low, 1.0–3.0 mg/L average, >3.0 mg/L high. Values above 10 mg/L usually reflect acute infection or inflammation rather than chronic cardiovascular risk — re-test once well.
PMID 12551878 →